Been tracking some interesting technical setups lately, and there's this pattern that keeps showing up - the golden cross. It's when a stock's 50-day moving average breaks above the 200-day, and it's one of those signals that actually moves markets. Algos love it, retail traders pile in, and volume usually spikes. Not foolproof, but worth paying attention to.

I've been looking at three names that caught my eye for potential golden cross momentum plays. First up is Sun Communities (SUI). The stock's been pretty flat through 2025, but there's something brewing here. The company operates manufactured home communities, and honestly, it's becoming a solid alternative for first-time buyers and people looking to downsize. The financing angle is interesting too - not everyone can get traditional mortgages, so this fills a gap. Analysts are seeing maybe 12% upside from where it closed in December. Plus, 2026 could be a decent year for REITs if interest rates keep moving lower. That dividend appeal matters when yields are attractive.

Then there's Darling Ingredients (DAR). This one's already moved over 9% in the last month while most things were selling off. They convert bio-nutrient streams into sustainable food, feed, and renewable fuels. The real catalyst? Biofuel policy is looking favorable heading into 2026, which should support strong demand for fats and used cooking oil. They just reported solid earnings in late October with 10% YOY revenue growth and 9% EPS growth. The consensus price target is sitting at $45.33, which is north of 27% above current levels. Analysts are expecting 44% earnings growth over the next 12 months. This one feels like a golden cross candidate that could have real legs.

Last one's a pure momentum trade - Wave Life Sciences (WVE). This stock absolutely ripped nearly 180% in a single day back in December after Phase 1 obesity drug results came through. The obesity treatment market is massive right now with Eli Lilly and Novo Nordisk dominating, but there's room for more players. Even after that huge move, analysts think there's another 30% upside to the consensus target of $27.46. Catch though - this is a clinical-stage company with minimal revenue. Getting this drug approved is probably two years out, so you need patience.

The thing about golden cross stocks is they can signal real momentum shifts, but you've got to do your homework. For income-focused investors, you want fundamentals backing up the technical signal. For traders chasing pure momentum, it's about timing and risk management. Either way, these three are worth keeping on your radar if you're looking at potential setups.